Antibacterial activity against a selection of Gram-positive strains, toxicity data in HuDe cells and human red blood cells and therapeutic indices (TI) for the 10 synthesised lead compounds^a.

	MIC [μM] vs. Gram-positive bacteria						Toxicity [μM]
	MRSA	MSSA	Se	Bs	En	En VRE	CC50	HC50	TI
MnC5MeIm	3.13–6.25	12.5–6.25	12.5	12.5–6.25	25	25	46.1 ± 0.1	>200	7
MnA3Clo	1.56	1.56	3.13	3.13–1.56	6.25	3.13	37.1 ± 0.2	68 ± 15	24
MnC8MeBeIm	3.13–1.56	6.25	6.25	6.25	12.5	6.25	18.0 ± 0.2	77 ± 10	6
MnC9MeBeIm	3.13–1.56	3.13	6.25	3.13	12.5	12.5	16.8 ± 0.2	95 ± 13	5
MnE2MeBeIm	3.13–1.56	3.13	6.25–3.13	3.13	12.5	12.5	7.2 ± 0.3	49 ± 12	2
MnG9MeBeIm	0.78	<0.78	<0.78	3.13–1.56	6.25	6.25	85.2 ± 0.1	117 ± 12	109
MnC1DMAP	3.13–1.56	3.13–1.56	6.25	6.25–3.13	12.5	6.25	37.0 ± 0.2	>200	12
MnD8DMAP	1.56	1.56–0.78	1.56	3.13–1.56	12.5	12.5	7.9 ± 0.2	>200	5
MnD9DMAP	1.56	1.56	3.13	1.56	12.5	6.25	9.4 ± 0.2	>200	6
MnE6Quin	6.25–3.13	6.25	12.5–6.25	6.25	50	25	36.3 ± 0.1	>200	6
VAN [μg mL−1]	1	1	1	0.25	1	8

^aAntibacterial activity is displayed as MIC [μM]. MRSA – methicillin resistant S. aureus; MSSA – methicillin susceptible S. aureus; Se – S. epidermidis; Bs – Bacillus subtilis; En – Enterococcus spp En VRE – Enterococcus casselliflavus VRE, CC₅₀ – HuDe cells; HC₅₀ – human red blood cells; TI – therapeutic index, determined by dividing the lowest value between CC₅₀ and HC₅₀ with the lowest MIC value for each compound; VAN – vancomycin. MIC determined with n = 4 across two biological replicates.